2019
Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Ippolito D, Querques G, Pecorelli A, Franzesi C, Okolicsanyi S, Strazzabosco M, Sironi S. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal Of Computer Assisted Tomography 2019, Publish Ahead of Print: &na;. PMID: 30407241, DOI: 10.1097/rct.0000000000000807.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaProgressive diseasePartial responseDynamic contrast-enhanced perfusionPerfusion CT valuesHepatic perfusion indexResponse Evaluation CriteriaMultifocal hepatocellular carcinomaIntravenous bolus injectionBlood flow changesContrast-enhanced perfusionRow Computed TomographyPerfusion CT techniquesStandard of referenceNonprogressor groupProgressor groupSorafenib administrationCirrhotic patientsArterial perfusionHepatic perfusionPD patientsTumor responsePerfusion indexTherapeutic response
2018
Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions
Ippolito D, Querques G, Okolicsanyi S, Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. European Journal Of Radiology 2018, 106: 62-68. PMID: 30150052, DOI: 10.1016/j.ejrad.2018.07.012.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaAnti-angiogenic therapyPerfusion CT imagingHepatocellular carcinomaPerfusion parametersProgressor groupSurvival rateNon-progressor groupOverall survival rateKaplan-Meier analysisAssessment of responseAntiangiogenetic treatmentCirrhotic patientsSorafenib administrationPrognostic indicatorTumor responseTarget lesionsHCC lesionsIndividualized treatmentTumor neoangiogenesisPatientsOverall populationHigher survival rateCT imagingSurvival predictionThe optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities
Cortesi P, Belli L, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani L, Strazzabosco M, Association T. The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities. Journal Of Viral Hepatitis 2018, 25: 791-801. PMID: 29406608, DOI: 10.1111/jvh.12877.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaDCC patientsTreatment strategiesIntestine Transplant AssociationProgression of HCVTransplant-eligible patientsHepatitis C therapyTransplant-related factorsCohort of patientsTime of transplantationDecision analytical modelCost-effectiveness analysisDAA effectivenessDAA treatmentEuropean LiverHCC presencePre-LTMELD scoreC therapyCirrhotic patientsDisease recurrenceTransplant centersSpecific regimenTransplant AssociationPatient level
1999
The monoethylglycinexylidide test for grading of liver cirrhosis
FABRIS, JEMMOLO, TOFFOLO, PALEARI, VIAGGI, RIGON, CASAGRANDE, LIRUSSI, STRAZZABOSCO, COBELLI, OKOLICSANYI. The monoethylglycinexylidide test for grading of liver cirrhosis. Alimentary Pharmacology & Therapeutics 1999, 13: 67-75. PMID: 9892881, DOI: 10.1046/j.1365-2036.1999.00431.x.Peer-Reviewed Original ResearchConceptsLiver function testsCirrhotic patientsLignocaine injectionLiver cirrhosisFunction testsMEGX testMEGX concentrationsDynamic liver function testsQuantitative liver function testsCompensated liver cirrhosisGood diagnostic accuracyMonoethylglycinexylidide formationMonoethylglycinexylidide testMEGX formationSerum concentrationsPatientsDisease severityMin-1Diagnostic accuracyCirrhosisOptimal sampling timesGood discriminationInjectionNormals
1984
Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
Okolicsanyi L, Venuti M, Strazzabosco M, Orlando R, Nassuato G, Iemmolo R, Lirussi F, Muraca M, Pastorino A, Castelli G. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis. International Journal Of Clinical Pharmacology And Therapeutics 1984, 22: 329-32. PMID: 6086536.Peer-Reviewed Original ResearchConceptsCompensated liver cirrhosisLiver cirrhosisPharmacokinetics of ranitidineCirrhotic patientsUrinary recoveryUnchanged drugHealthy controlsPlasma concentrationsIntravenous pharmacokineticsPharmacokinetic dataPatientsCirrhosisOral bioavailabilityRanitidinePharmacokineticsHigh-performance liquid chromatographyPerformance liquid chromatographyCirrhoticsLiquid chromatographyControlThe pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
Okolicsányi L, Venuti M, Strazzabosco M, Iemmolo R, Nassuato G, Orlando R, Lirussi F. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis. Physiology International 1984, 64: 393-400. PMID: 6099684.Peer-Reviewed Original ResearchConceptsCompensated liver cirrhosisLiver cirrhosisPlasma concentrationsUrinary recoveryOral administrationDoses of cimetidinePharmacokinetics of cimetidineHigher plasma concentrationsSame plasma concentrationIntravenous cimetidineCirrhotic patientsSingle dosesH2 receptorsOral routeNormal subjectsPharmacokinetic parametersAdministration routeCimetidineRanitidineCirrhosisPharmacokineticsDosesPatientsAdministration